Fragment-based drug design (FBDD) has become an effective methodology for drug development for decades. Successful applications of this strategy brought both opportunities and challenges to the field of Pharmaceutical Science. Recent progress in the computational fragment-based drug design provide an additional approach for future research in a time- and labor-efficient manner. Combining multiple in silico methodologies, computational FBDD possesses flexibilities on fragment library selection, protein model generation, and fragments/compounds docking mode prediction. These characteristics provide computational FBDD superiority in designing novel and potential compounds for a certain target. The purpose of this review is to discuss the latest advances, ranging from commonly used strategies to novel concepts and technologies in computational fragment-based drug design. Particularly, in this review, specifications and advantages are compared between experimental and computational FBDD, and additionally, limitations and future prospective are discussed and emphasized.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9(5):580–8.
Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 2007;6(3):211–9.
Sheng C, Zhang W. Fragment informatics and computational fragment-based drug design: an overview and update. Med Res Rev. 2013;33(3):554–98.
Congreve M, Carr R, Murray C, Jhoti H. A ‘rule of three’ for fragment-based lead discovery? Drug Discov Today. 2003;8(19):876–7.
Jhoti H, Williams G, Rees DC, Murray CW. The ‘rule of three’ for fragment-based drug discovery: where are we now? Nat Rev Drug Discov. 2013;12(8):644–5.
Koster H, Craan T, Brass S, Herhaus C, Zentgraf M, Neumann L, et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J Med Chem. 2011;54(22):7784–96.
Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. J Med Chem. 2008;51(13):3661–80.
Murray CW, Callaghan O, Chessari G, Cleasby A, Congreve M, Frederickson M, et al. Application of fragment screening by X-ray crystallography to beta-secretase. J Med Chem. 2007;50(6):1116–23.
Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, et al. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science. 2008;321(5896):1673–5.
Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol. 2005;23(2):201–7.
Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol. 2009;5(5):358–64.
Hashem IAT, Yaqoob I, Anuar NB, Mokhtar S, Gani A, Khan SU. The rise of “big data” on cloud computing: review and open research issues. Inf Syst. 2015;47:98–115.
Ray PC, Kiczun M, Huggett M, Lim A, Prati F, Gilbert IH, et al. Fragment library design, synthesis and expansion: nurturing a synthesis and training platform. Drug Discov Today. 2017;22(1):43–56.
Keserű GM, Erlanson DA, Ferenczy GG, Hann MM, Murray CW, Pickett SD. Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia. J Med Chem. 2016;59(18):8189–206.
Yuriev E, Holien J, Ramsland PA. Improvements, trends, and new ideas in molecular docking: 2012–2013 in review. J Mol Recognit. 2015;28(10):581–604.
Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mol Recognit. 2013;26(5):215–39.
Wang L, Xie Z, Wipf P, Xie X-Q. Residue preference mapping of ligand fragments in the protein data bank. J Chem Inf Model. 2011;51(4):807–15.
Myint K, Ma C, Wang L, Xie X-Q. Fragment-similarity-based QSAR (FS-QSAR) algorithm for ligand biological activity predictions. SAR QSAR Environ Res. 2011;22(3–4):385–410.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.
Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol. 1995;245(1):43–53.
Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–48.
Jain AN. Surflex-dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des. 2007;21(5):281–306.
Bohnuud T, Luo L, Wodak SJ, Bonvin AM, Weng Z, Vajda S, et al. A benchmark testing ground for integrating homology modeling and protein docking. Proteins: Structure, Function, and Bioinformatics. 2017;85(1):10–6.
Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov Today. 2009;14(13):676–83.
Webb B, Sali A. Protein structure modeling with MODELLER. Protein Structure Prediction. 2014:1–15.
Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003;31(13):3381–5.
Chung S, Parker JB, Bianchet M, Amzel LM, Stivers JT. Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol. 2009;5(6):407–13.
Kawai K, Nagata N, Takahashi Y. De novo design of drug-like molecules by a fragment-based molecular evolutionary approach. J Chem Inf Model. 2014;54(1):49–56.
Guvench O. Computational functional group mapping for drug discovery. Drug Discov Today. 2016;21(12):1928–31.
Chen H, Zhou X, Wang A, Zheng Y, Gao Y, Zhou J. Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov Today. 2015;20(1):105–13.
Speck-Planche A, Cordeiro MND. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins. Mol Divers. 2017:1–13.
Garcia-Jacas CR, Marrero-Ponce Y, Acevedo-Martinez L, Barigye SJ, Valdes-Martini JR, Contreras-Torres E. QuBiLS-MIDAS: a parallel free-software for molecular descriptors computation based on multilinear algebraic maps. J Comput Chem. 2014;35(18):1395–409.
Hao GF, Jiang W, Ye YN, Wu FX, Zhu XL, Guo FB, et al. ACFIS: a web server for fragment-based drug discovery. Nucleic Acids Res. 2016;44(W1):W550–6.
Li Y, Zhao Z, Liu Z, Su M, Wang R. AutoT&T v.2: an efficient and versatile tool for lead structure generation and optimization. J Chem Inf Model. 2016;56(2):435–53.
Pevzner Y, Frugier E, Schalk V, Caflisch A, Woodcock HL. Fragment-based docking: development of the CHARMMing Web user interface as a platform for computer-aided drug design. J Chem Inf Model. 2014;54(9):2612–20.
Douguet D. e-LEA3D: a computational-aided drug design web server. Nucleic Acids Res. 2010;38(Web Server):W615–21.
Liu T, Naderi M, Alvin C, Mukhopadhyay S, Brylinski M. Break down in order to build up: decomposing small molecules for fragment-based drug design with e MolFrag. J Chem Inf Model. 2017;57(4):627–31.
Naderi M, Alvin C, Ding Y, Mukhopadhyay S, Brylinski M. A graph-based approach to construct target-focused libraries for virtual screening. J Cheminformatics. 2016;8(1):14.
Fechner U, Schneider G. Flux (1): a virtual synthesis scheme for fragment-based de novo design. J Chem Inf Model. 2006;46(2):699–707.
Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, et al. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat Protoc. 2015;10(5):733–55.
Tsai TY, Chang KW, Chen CY. iScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan. J Comput Aided Mol Des. 2011;25(6):525–31.
Yuan Y, Pei J, Lai L. LigBuilder 2: a practical de novo drug design approach. J Chem Inf Model. 2011;51(5):1083–91.
Damewood JR, Jr., Lerman CL, Masek BB. NovoFLAP: a ligand-based de novo design approach for the generation of medicinally relevant ideas. J Chem Inf Model 2010;50(7):1296–1303.
Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand JS, Ben Jelloul M, et al. Identify drug repurposing candidates by mining the protein data bank. Brief Bioinform. 2011;12(4):336–40.
Ghersi D, Singh M. molBLOCKS: decomposing small molecule sets and uncovering enriched fragments. Bioinformatics. 2014;30(14):2081–3.
Hoffer L, Chira C, Marcou G, Varnek A, Horvath D. S4MPLE—sampler for multiple protein-ligand entities: methodology and rigid-site docking benchmarking. Molecules. 2015;20(5):8997–9028.
Liu X, Jiang H, Li H. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening. J Chem Inf Model. 2011;51(9):2372–85.
Yu W, Xiao H, Lin J, Li C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013;56(11):4402–12.
Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, et al. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2016;7(15):19863–83.
Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–8.
Bian Y, Feng Z, Yang P, Xie XQ. Integrated in silico fragment-based drug design: case study with allosteric modulators on metabotropic glutamate receptor 5. AAPS J. 2017;19(4):1235–48.
Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol. 2014;54:165–84.
Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48(1):1–14.
Hubbard RE, Chen I, Davis B. Informatics and modeling challenges in fragment-based drug discovery. Curr Opin Drug Discov Devel. 2007;10(3):289–97.
Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384–421.
The authors would like to acknowledge the funding supports to the Xie laboratory from the NIH NIDA (P30 DA035778A1) and DOD (W81XWH-16-1-0490). The first author would like to thank Jie in particular, for the consistant support, love, and the memorable and solemn wedding. How lucky the first author is to have Jie as his bride!
Conflict of Interest
The authors declare that they have no competing interest.
Guest Editor: Xiang-Qun Xie
About this article
Cite this article
Bian, Y., Xie, XQ.(. Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications. AAPS J 20, 59 (2018). https://doi.org/10.1208/s12248-018-0216-7
- fragment-based drug design
- fragment database
- drug discovery
- fragment docking
- virtual screening